Fax:2123183400

RESENTED Jul 13-2000 - P. 07

JUL 13 2009

PTO/SB/26 (02-09)

Approved for use through 03/31/2009. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

sired to respond to a collection of information unless it displays a valid OMB control number. $\frac{1}{2}$, the second contract of the second contract of $\frac{1}{2}$

1	TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING	Docket Number (Optional)	
	REJECTION OVER A "PRIOR" PATENT	NY-LUD 5253-US5-DIV	
	In re Application of: Thierry Boon-Falleur et al.		
	- Application No.: 08/819,669-Conf. #1995		
!	Filed: March 17, 1997		
	TUMOR REJECTION, ANTIGEN PRECURSORS, TUMOR REJECTION ANTIGEN S AND USES THEREOF		
	The owner, LUDWIG INSTITUTE FOR CANCER RESEARCH , of instant application hereby disctalms, except as provided below, the terminal part of the statutor instant application which would extend beyond the expiration date of the full statutory term of price as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said play any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant only for and during such period that it and the prior patent are commonly owned. This agreed on the instant application and is binding upon the grantee, its successors or assigns.	y term of any patent granted on the present No. 5,843,448 prior patent is presently shortened and application shall be enforceable	
	Further, the owner walves the right to separately enforce any granted on application 08/819,669 or any patent subject to re- examination proceedings, as well as U.S. Patent No. 5,843,448. The owner further states that any patent granted on application 09/819,669 or any patent subject to re-examination proceedings shall be enforced only for and during such period that the patent and the patent, or any patent granted on application 08/819,669, which formed the basis for the double patenting are not		
·	In making the above disclaimer, the owner does not disclaim the terminal part of the term of application that would extend to the expiration date of the full statutory term as defined in application that would extend to the expiration date of the full statutory term as defined in patent. "as the term of said prior patent is presently shortened by any terminal disclaimer," later:	of any patent granted on the instant 35 U.S.C. 164 and 173 of the prior In the event that said prior patent	
	expires for failure to pay a maintenance fee; is held unenforceable; is found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexamination certificate;	· · · · · · · · · · · · · · · · · · ·	
	has all claims cancated by a reexamination of masses, is reissued; or	ortoned by any terminal disclaimer.	
	is reissued; or is in any manner terminated prior to the expiration of its full statutory term as presently sho	of territory and territories described	
	Check either box.1.or 2 below, if appropriate.		
	1. For submissions on behalf of a business/organization (e.g., corporation, partnersl etc.), the undersigned is empowered to act on behalf of the business/organization		
	I hereby declare that all statements made herein of my own knowledge are true and that and belief are believed to be true; and further that these statements were made with the knowledge are punishable by fine or imprisonment, or both, under Section 1001 and that such willful false statements may jeopardize the validity of the application or any page.	t all statements made on information nowledge that willful false statements of Title 18 of the United States Code	
•	2. X The undersigned is an attorney or agent of record. Reg. No. 30,94	6	
	2. The undersigned is an autometry of age.	7/13/09 Date	
	Signature	,	
	Norman D. Hanson		
	Typed or printed name		
		(212) 318-3168 Telephone Number	
	X Charge Terminal disclaimer fee under 37 CFR 1.20(d) to Credit Card. PTO Form		
	WARNING: Information on this form may become public. Credit of be included on this form. Provide credit card information and auti	and information should not	
	*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assigner form PTO/SB/96 may be used for making this certification. See MPEP § 324.		
	50184201.1		

PAGE 7/9 * RCVD AT 7/13/2009 2:24:09 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-5/9 * DNIS:2738300 * CSID:2123183400 * DURATION (mm-ss):02-32